SG11201807301SA - Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors - Google Patents
Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitorsInfo
- Publication number
- SG11201807301SA SG11201807301SA SG11201807301SA SG11201807301SA SG11201807301SA SG 11201807301S A SG11201807301S A SG 11201807301SA SG 11201807301S A SG11201807301S A SG 11201807301SA SG 11201807301S A SG11201807301S A SG 11201807301SA SG 11201807301S A SG11201807301S A SG 11201807301SA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- international
- limited
- moneta
- mission
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111 011010111 11111 011011100 111110 ill OEN 11 International Bureau .. .... ..Yejd ..... .....!;,..1 (10) International Publication Number (43) International Publication Date WO 2017/149313 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (Building 280), Cambridge Cambridgeshire CB22 3AT C07D 471/10 (2006.01) A61K 31/537 (2006.01) (GB). CO7D 471/20 (2006.01) A61P 35/00 (2006.01) CO7D 498/20 (2006.01) A61P 29/00 (2006.01) (74) Agent: STRATAGEM IPM LIMITED; Meridian Court, A61K 31/4353 (2006.01) Comberton Road, Toft, Cambridge CB23 2RY (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2017/050565 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 2 March 2017 (02.03.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 1603779.8 4 March 2016 (04.03.2016) GB TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant: MISSION THERAPEUTICS LIMITED ZA, ZM, ZW. [GB/GB]; Babraham Research Campus, Moneta Building (84) Designated States (unless otherwise indicated, for every (Building 280), Cambridge Cambridgeshire CB22 3AT kind of regional protection available): ARIPO (BW, GH, (GB). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: KEMP, Mark Ian; c/o Mission Therapeutics TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, — Limited, Babraham Research Campus, Moneta Building TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, _ (Building 280), Cambridge Cambridgeshire CB22 3AT DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (GB). STOCKLEY, Martin Lee; c/o Mission Therapeut- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, = ics Limited, Babraham Research Campus, Moneta Building SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (Building 280), Cambridge Cambridgeshire CB22 3AT GW, KM, ML, MR, NE, SN, TD, TG). (GB). WOODROW, Michael David; c/o Mission Thera- Published: peutics Limited, Babraham Research Campus, Moneta = Building (Building 280), Cambridge Cambridgeshire CB22 with international search report (Art. 21(3)) = 3AT (GB). JONES, Alison; c/o Mission Therapeutics — Limited, Babraham Research Campus, Moneta Building = = = (54) Title: SPIRO-CONDENSED PYRROLIDINE DERIVATIVES = = = = = 7 H N %,.. AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS „la ri 1.? r, K SE Ny __ A N * tr 1-1 M 1-1 en CI' iv 1-1 IN 1-1 (57) : The present invention relates to novel compounds N enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer. (Figure (I)) 1k: 1 f 1 ti (I) and methods for the manufacture of inhibitors of deubiquitylating
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603779.8A GB201603779D0 (en) | 2016-03-04 | 2016-03-04 | Novel compounds |
| PCT/GB2017/050565 WO2017149313A1 (en) | 2016-03-04 | 2017-03-02 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807301SA true SG11201807301SA (en) | 2018-09-27 |
Family
ID=55859019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807301SA SG11201807301SA (en) | 2016-03-04 | 2017-03-02 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10654853B2 (en) |
| EP (2) | EP4067355A1 (en) |
| JP (2) | JP6959247B2 (en) |
| KR (1) | KR102384139B1 (en) |
| CN (1) | CN108602823B (en) |
| AU (1) | AU2017225371B2 (en) |
| BR (1) | BR112018017086B1 (en) |
| CA (1) | CA3016370C (en) |
| CO (1) | CO2018009275A2 (en) |
| ES (1) | ES2919549T3 (en) |
| GB (1) | GB201603779D0 (en) |
| HK (1) | HK1258589A1 (en) |
| IL (1) | IL261552B (en) |
| MA (1) | MA43701A (en) |
| MY (1) | MY196836A (en) |
| RU (1) | RU2730552C2 (en) |
| SG (1) | SG11201807301SA (en) |
| WO (1) | WO2017149313A1 (en) |
| ZA (1) | ZA201803910B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016156816A1 (en) | 2015-03-30 | 2016-10-06 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| ES2773046T3 (en) | 2015-07-14 | 2020-07-09 | Mission Therapeutics Ltd | Cyanopyrrolidines as DUB inhibitors for cancer treatment |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) * | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| JP6959252B2 (en) | 2016-03-24 | 2021-11-02 | ミッション セラピューティクス リミティド | 1-Cyanopyrrolidine derivative as a DUB inhibitor |
| WO2018060689A1 (en) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (en) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | Novel compounds |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3642196B1 (en) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as dub inhibitors |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| WO2020036940A1 (en) | 2018-08-14 | 2020-02-20 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| ES2945834T3 (en) | 2018-10-05 | 2023-07-07 | Forma Therapeutics Inc | Fused pyrrolines that act as inhibitors of ubiquitin-specific protease 30 (USP30) |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CA3171349A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| KR20230016674A (en) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | N-(1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and corresponding Oxadiazole derivatives |
| BR112022019722A2 (en) | 2020-06-04 | 2022-12-20 | Mission Therapeutics Ltd | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS |
| JP2023528087A (en) | 2020-06-08 | 2023-07-03 | ミッション セラピューティクス リミティド | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3] as USP30 inhibitors used in the treatment of mitochondrial dysfunction, cancer, and fibrosis ,4-b]pyrrole-5(1H)-carbonitrile |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| CN116143782B (en) * | 2021-11-22 | 2024-04-12 | 西南大学 | Design synthesis and application of spiro [ pyrrolidine-2, 3 '-quinoline ] -2' -ketone derivatives |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835727B2 (en) | 2000-04-06 | 2004-12-28 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| BRPI0715506A2 (en) * | 2006-08-30 | 2014-07-08 | Univ Michigan | NEW SMALL INHIBITORS MDM2 AND USES OF THE SAME |
| WO2008144507A2 (en) | 2007-05-16 | 2008-11-27 | President And Fellows Of Harvard College | Spirooxindole inhibitors of aurora kinase |
| WO2009026197A1 (en) * | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Novel cathepsin c inhibitors and their use |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| HUE038714T2 (en) * | 2011-03-10 | 2018-11-28 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| WO2016156816A1 (en) | 2015-03-30 | 2016-10-06 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| ES2773046T3 (en) | 2015-07-14 | 2020-07-09 | Mission Therapeutics Ltd | Cyanopyrrolidines as DUB inhibitors for cancer treatment |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) * | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| JP6959252B2 (en) | 2016-03-24 | 2021-11-02 | ミッション セラピューティクス リミティド | 1-Cyanopyrrolidine derivative as a DUB inhibitor |
| WO2018060689A1 (en) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (en) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | Novel compounds |
-
2016
- 2016-03-04 GB GBGB1603779.8A patent/GB201603779D0/en not_active Ceased
-
2017
- 2017-03-02 US US16/078,518 patent/US10654853B2/en active Active
- 2017-03-02 MA MA043701A patent/MA43701A/en unknown
- 2017-03-02 JP JP2018546518A patent/JP6959247B2/en active Active
- 2017-03-02 EP EP22172828.0A patent/EP4067355A1/en active Pending
- 2017-03-02 ES ES17709766T patent/ES2919549T3/en active Active
- 2017-03-02 CA CA3016370A patent/CA3016370C/en active Active
- 2017-03-02 AU AU2017225371A patent/AU2017225371B2/en active Active
- 2017-03-02 CN CN201780010388.5A patent/CN108602823B/en active Active
- 2017-03-02 EP EP17709766.4A patent/EP3423454B1/en active Active
- 2017-03-02 SG SG11201807301SA patent/SG11201807301SA/en unknown
- 2017-03-02 KR KR1020187028269A patent/KR102384139B1/en active IP Right Grant
- 2017-03-02 MY MYPI2018001499A patent/MY196836A/en unknown
- 2017-03-02 WO PCT/GB2017/050565 patent/WO2017149313A1/en active Application Filing
- 2017-03-02 RU RU2018133279A patent/RU2730552C2/en active
- 2017-03-02 BR BR112018017086-0A patent/BR112018017086B1/en active IP Right Grant
-
2018
- 2018-06-12 ZA ZA2018/03910A patent/ZA201803910B/en unknown
- 2018-09-02 IL IL261552A patent/IL261552B/en active IP Right Grant
- 2018-09-04 CO CONC2018/0009275A patent/CO2018009275A2/en unknown
-
2019
- 2019-01-18 HK HK19100946.4A patent/HK1258589A1/en unknown
-
2020
- 2020-04-08 US US16/843,408 patent/US11236092B2/en active Active
-
2021
- 2021-09-29 JP JP2021158986A patent/JP7280928B2/en active Active
- 2021-12-14 US US17/550,071 patent/US20220106315A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor |